Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Articles & Research
from hVIVO

A Key Endpoint in Viral Challenge Models of Asthma Exacerbations

Human Rhinovirus (HRV) is reported to be a leading cause of up to 80% of asthma exacerbations. The viral pathway and associated immune responses represent a potential key therapeutic target...

Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model

hVIVO's presentation during the Options X conference in 2019 about pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model.

The Human Viral Challenge Model with A/PERTH/16/2009 H3N2A systematic analysis from five clinical studies

The human viral challenge model is well established, safe and ideal to study influenza. It allows researchers to illuminate each step of the infection: baseline, peak and return to healthy....

hVIVO is Gold Sponsor and presenter at World Vaccine Congress, Washington DC, USA April 2019

WVC 2017, 14-17 April 2019, Renaissance Washington DC Downtown Hotel, Washington DC, USA hVIVO is proud to once again be a Gold Sponsor of the World Vaccine Congress 2019, a...

hVIVO and Imutex Limited to present at IVW 2019 conference, Edinburgh, Scotland, April

Influenza Vaccines For The World 2019, April 02 - 04, Edinburgh, Scotland. hVIVO and its joint venture, Imutex Limited, will present at the Influenza Vaccines for the World (IVW 2019)...

hVIVO's Alex Mann making an oral presentation at ISRIV 1st Influenza Vaccine Group Meeting, Siena, Italy, March

ISRIV 1st Influenza Vaccine Group Meeting, March 31st - April 2nd, Siena, Italy Alex Man, hVIVO’s Director Clinical Science R&D Operations, will be making an oral presentation at ISRIV 1st Influenza...